HB5804 amends Section 5-5.12 of the Illinois Public Aid Code, which governs pharmacy payments under Medicaid. The bill requires Medicaid managed care organizations, including when they use pharmacy benefit managers, to reimburse non-critical access pharmacy providers for dispensing fees and drug acquisition costs at no less than the amounts paid under the fee-for-service Medicaid program. The requirement applies broadly to pharmacy services for people receiving benefits under the Code, including services reimbursed under Section 5-36.
The measure is aimed at aligning managed care pharmacy reimbursement with the state’s fee-for-service rates and preventing lower payment levels for pharmacies serving Medicaid patients. It preserves existing Department authority over pharmacy reimbursement, utilization controls, prior approval, and related drug management provisions, but adds a floor for managed care reimbursement to protect pharmacy providers from being paid less than fee-for-service benchmarks.
If enacted, the bill would amend the Illinois Public Aid Code to create a statutory reimbursement parity requirement for Medicaid managed care organizations and any pharmacy benefit managers they contract with. It would affect pharmacy providers that are not critical access care pharmacies by guaranteeing at least fee-for-service levels for dispensing fees and acquisition costs, while leaving the broader Medicaid pharmacy payment and utilization framework in place. The practical effect would be to increase or stabilize reimbursement for many community pharmacies serving Medicaid managed care enrollees and could increase costs for managed care plans and their contractors.
No committee transcripts or recorded votes were provided, so there is no direct evidence of debate or formal support/opposition in the materials supplied. Based on the bill text alone, the measure appears to be provider-focused and intended to address reimbursement concerns in Medicaid managed care, which typically suggests support from pharmacy stakeholders and possible caution from managed care organizations and state budget officials. The absence of recorded action in the provided context prevents a more specific assessment of legislative sentiment.
The main point of contention is likely the reimbursement mandate itself: pharmacies would benefit from a guaranteed payment floor, while Medicaid managed care organizations and pharmacy benefit managers may object to the added cost and reduced flexibility in setting rates. Another possible issue is the bill’s exclusion of critical access care pharmacies from the new requirement, which could raise questions about why some providers are treated differently. The bill also preserves existing utilization controls and Department oversight, so any dispute would center less on drug management policy and more on who bears the financial burden of Medicaid pharmacy payments.